Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Dec. 29, 2021 12:35 UTC

GUANGZHOU, China--(BUSINESS WIRE)-- Bio-Thera Solutions, Ltd.   (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers. BAT6005 was discovered using Bio-Thera’s proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform, and it has normal IgG1 ADCC function.

“TIGIT is an immune-oncology drug target of significant interest. Preclinical data generated in support of the BAT6005 IND is very promising.” Said Dr. Jin-Chen Yu, SVP, Bio-Thera Solutions. “BAT6005 is one of several IO assets that are entering Phase 1 studies and transition Bio-Thera’s innovative IO pipeline from primarily a preclinical pipeline to a clinical pipeline. We plan to explore combinations of BAT6005 with BAT1308, our novel PD-1 antibody, to treat a broad range of cancers.”

The Phase 1, multicenter, open-label, dose-escalation clinical trial of BAT6005 is designed to assess the safety and tolerability of BAT6005 as a single agent. The study is expected to enroll subjects with advanced solid tumor. Key objectives in the study include determining maximum tolerated dose, pharmacokinetics and preliminary anti-tumor activity. Disease-specific expansion cohorts will be enrolled at the maximally tolerated or biologically relevant dose.

About IDEAL Platform

Bio-Thera Solutions has developed a proprietary fully synthetic human antibody discovery platform called IDEAL, which stands for Intelligent Design and Engineered Antibody Libraries Platform. The CDR-H3 of our novel innovative antibodies is designed based on over 100,000 natural human antibody sequences. Our IDEAL library has an overall diversity of CDR-H3 over 3E+11. Fixed clinically proven frameworks are utilized to increase the odds of development. A universal affinity maturation library is used for all candidates. A fast high-throughput screening platform is employed.

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in the next generation antibody discovery and engineering, the company has advanced six candidates into late-stage clinical trials and two of them, QLETLI® and POBEVCY®, are available to patients in China. In addition, the company has multiple candidates in early stage clinical or entering clinical studies, including differentiated and innovative anti-OX40, anti-TIGIT, and anti-PD-L1/CD47 bispecific antibodies. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).

Cautionary Note Regarding Forward-Looking Statements

This news release contains certain forward-looking statements relating to BAT6005 or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing “could,” “may,” “should,” “will,” “would,” “anticipate,” “believe,” “plan,” “promising,” “potentially,” or similar expressions. They reflect the company’s current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies, for example, the development processes could be lengthy and high in vitro affinity may not translate to desired results in vivo or successful clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company’s financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company’s views or otherwise.

Contacts

Bio-Thera Solutions, Ltd.:
Bert E. Thomas IV +1.410.627.1734
bethomas@bio-thera.com

 
 

Source: Bio-Thera Solutions, Ltd.

Back to news